M
Michael Goggins
Researcher at Johns Hopkins University
Publications - 378
Citations - 52451
Michael Goggins is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 111, co-authored 358 publications receiving 45785 citations. Previous affiliations of Michael Goggins include Johns Hopkins University School of Medicine & Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Proximal Cholangiocarcinoma: Tumor Depth Predicts Outcome
Mathew M. Augustine,Seung-Mo Hong,M. de Jong,Michael Goggins,Richard D. Schulick,Christopher L. Wolfgang,Barish H. Edil,Michael A. Choti,Robert A. Anders,Timothy M. Pawlik +9 more
Proceedings ArticleDOI
Abstract 2628: Genome-wide sequencing identifiesATMas a pancreatic cancer susceptibility gene
Nicholas J. Roberts,Yuchen Jiao,Jun Yu,Levy Kopelovich,Gloria M. Petersen,Melissa L. Bondy,Steven Gallinger,Ann G. Schwartz,Sapna Syngal,Michele L. Cote,Jennifer E. Axilbund,Richard D. Schulick,Syed Z. Ali,James R. Eshleman,Victor E. Velculescu,Michael Goggins,Bert Vogelstein,Nikolas Papadopoulous,Ralph H. Hruban,Kenneth W. Kinzler,Alison P. Klein +20 more
TL;DR: It is indicated that ATM mutations play an important role in familial pancreatic cancer predisposition and have significant implications in the management of affected individuals and the risk assessment of family members.
Journal ArticleDOI
Validation Strategy for Ultrasensitive Mutation Detection.
Marija Debeljak,Michaël Noë,Stacy L. Riel,Lisa Haley,Alexis L. Norris,Derek A. Anderson,Emily Adams,Masaya Suenaga,Katie Beierl,Ming Tseh Lin,Michael Goggins,Christopher D. Gocke,James R. Eshleman,James R. Eshleman +13 more
TL;DR: The VAF correction was found to be more significant than haplotype correction and it is imperative that various technologies be evaluated against each other and laboratories be provided with defined quality control samples for proficiency testing.
Journal ArticleDOI
Intercepting Pancreatic Cancer: Our Dream Team's Resolve to Stop Pancreatic Cancer.
Michael Goggins,Michael Goggins,Scott M. Lippman,Pamela E. Constantinou,Tyler Jacks,Gloria M. Petersen,Sapna Syngal,Anirban Maitra +7 more
TL;DR: The Stand Up to Cancer Pancreatic Interception Dream Team kicked off initiatives in a targeted effort to revolutionize the outcomes of those at risk for developing pancreatic cancer, and will leverage its multidisciplinary expertise to identify and screen high-risk cohorts, investigate innovative immune prevention strategies, and discover novel cancer biomarkers.
Journal ArticleDOI
A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer.
Saurav D. Haldar,Carol Judkins,Anna Ferguson,Elizabeth Abou Diwan,Su Jin Lim,Haiyan Wang,Julie M. Nauroth,Michael Goggins,Daniel A. Laheru,Elizabeth M. Jaffee,Nilofer S. Azad,Neeha Zaidi +11 more
TL;DR: In this paper , the safety and immunogenicity of a pooled synthetic long peptide (SLP) mKRAS vaccine in patients identified as high risk for developing pancreatic ductal adenocarcinoma (PDAC) based on family history and germline mutation testing was evaluated.